

Editorial Board ID: 00058511

Thessaloniki

December 6, 2023

Dr. Lian-Sheng Ma

Founder and Chief Executive Officer

Baishideng Publishing Group, Inc.

Dear Editor:

Thank you for your preliminary decision regarding our invited paper entitled “New trends in diagnosis and management of gallbladder carcinoma” (Manuscript NO: 89737), which was sent to the *World Journal of Gastrointestinal Oncology* for publication as a *Review*.

I would like to thank the reviewer for his earnest efforts in reviewing the manuscript. I have accepted all considerations expressed by the reviewer for improving the manuscript and have responded to them step by step. The changes are highlighted in yellow.

Reviewer 1

Many thanks for your considerable comments. Your concise review is very much appreciated.

1. An extended linguistic revision has been made. A professional Editing Certificate is included.

2. As suggested, the changing scenario of medical treatment has been clarified further by adding the following text: “***New directions and perspectives***

Summarizing the abovementioned recent treatment options, the following could be stressed. Surgery is the main therapeutic step; nevertheless, it is impracticable in most cases, and when it is achieved, it is often accompanied by recurrence. Neoadjuvant treatment may ensure better local control in a manner of downstaging the disease. Moreover, it allows a potential R0 resection, contributing to limited recurrence [175]. The use of 6 months of capecitabine treatment after therapeutic excision represents a standard cure. However, novel adjuvant

systemic treatment opens new perspectives [176]. The first-line treatment with cisplatin and gemcitabine combined with immune checkpoint inhibitors and targeted therapy has broadened the management horizons of advanced biliary tract carcinoma [177,178]" (page 22, lines 1-11). Thus, 4 new references (175-178) have been included.

3. The abstract has been modified as suggested.

I am sending the revised manuscript and hope to receive a favorable final decision.

We look forward to hearing from you at your earliest convenience.

Sincerely,

Theodoros E Pavlidis MD, PhD

Emeritus Professor of Surgery

School of Medicine

Aristotle University of Thessaloniki Greece

Hippocraton Hospital, Konstantinoupoleos 49, 546 42

2nd Propedeutic Department of Surgery

e-mail: pavlidth@auth.gr

Editorial Board ID: 00058511